Christian K Schneider (PharmaLex)

article

Many hands make light work: why the new Bespoke Gene Therapy Consortium is a godsend for ambitious biopharma teams

21 December 2021 | By Christian K Schneider (Biopharma Excellence), Christian K Schneider (PharmaLex)

In late October, we learned that an exciting and ambitious new entity – the Bespoke Gene Therapy Consortium (BGTC) – had come into being in the US, designed to encourage the delivery of more gene therapies for rare diseases. The consortium is an interesting construct, headed and funded by the…

article

Five marketing strategies for novel therapeutics

7 December 2021 | By Christian K Schneider (PharmaLex)

Long before the advent of Coronavirus, next-generation therapies were making headlines, but the successful development of COVID-19 vaccines, including mRNA vaccines, has now shone a spotlight on next-generation therapies. This offers a boost to the long-term growth projections for the advanced therapy medicinal products (ATMPs) sector. But although ATMPs hold…